Geode Capital Management, LLC Iveric Bio, Inc. Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$18.67 - $24.56 $3.21 Million - $4.23 Million	172,028 Added 7.12%	2,587,857 $63 Million
Q4 2022 Feb 13, 2023	BUY	$17.24 - $23.95 $6.12 Million - $8.51 Million	355,148 Added 17.23%	2,415,829 $51.7 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $701,672 - $1.39 Million	74,646 Added 3.76%	2,060,681 $37 Million
Q2 2022 Aug 12, 2022	SELL	$9.12 - $18.9 $41,696 - $86,410	-4,572 Reduced 0.23%	1,986,035 $19.1 Million
Q1 2022 May 13, 2022	BUY	$12.15 - $16.83 $136,031 - $188,428	11,196 Added 0.57%	1,990,607 $33.5 Million
Q4 2021 Feb 11, 2022	BUY	$13.83 - $18.78 $4.75 Million - $6.45 Million	343,337 Added 20.99%	1,979,411 $33.1 Million
Q3 2021 Nov 12, 2021	BUY	$7.07 - $17.5 $1.34 Million - $3.31 Million	189,008 Added 13.06%	1,636,074 $26.6 Million
Q2 2021 Aug 13, 2021	BUY	$5.69 - $7.17 $637,769 - $803,656	112,086 Added 8.4%	1,447,066 $9.13 Million
Q1 2021 May 12, 2021	BUY	$5.08 - $6.89 $947,049 - $1.28 Million	186,427 Added 16.23%	1,334,980 $8.25 Million
Q4 2020 Feb 12, 2021	BUY	$5.65 - $7.66 $476,860 - $646,504	84,400 Added 7.93%	1,148,553 $7.94 Million
Q3 2020 Nov 13, 2020	BUY	$4.01 - $6.29 $2 Million - $3.14 Million	499,350 Added 88.41%	1,064,153 $6 Million
Q2 2020 Aug 13, 2020	BUY	$3.06 - $6.6 $870,967 - $1.88 Million	284,630 Added 101.59%	564,803 $2.88 Million
Q1 2020 May 14, 2020	BUY	$2.83 - $8.44 $182,433 - $544,076	64,464 Added 29.88%	280,173 $963,000
Q4 2019 Feb 13, 2020	BUY	$0.93 - $8.58 $38,999 - $359,802	41,935 Added 24.13%	215,709 $1.85 Million
Q2 2019 Aug 14, 2019	BUY	$1.21 - $1.48 $210,266 - $257,185	173,774 New	173,774 $225,000

Others Institutions Holding ISEE

# of Institutions

Shares Held

250K

Call Options Held

40K

Put Options Held

View Full List

About IVERIC bio, Inc.

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

More about ISEE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account